Investment Rating - The report maintains a "Hold" rating for the pharmaceutical sector [7] Core Insights - The pharmaceutical industry is currently experiencing a shift towards innovation and international expansion, with significant growth expected in small nucleic acid therapies and supply chain management [5][4] - The report highlights the strong performance of CROs and certain upstream companies, indicating a positive trend in the market despite overall mixed performance in the pharmaceutical sector [3][4] - The report emphasizes the importance of clinical data releases in 2026, which could further validate the efficacy of small nucleic acid drugs and enhance market confidence [25][26] Summary by Sections Small Nucleic Acids - The commercialization of small nucleic acids is entering a high-growth phase, with notable sales increases for key products like Novartis' Leqvio and Alnylam's siRNA products [15][16] - The global transaction volume in the small nucleic acid sector surged to $36.5 billion in 2025, with major pharmaceutical companies actively acquiring small nucleic acid technology platforms [22] - Significant clinical data for small nucleic acid drugs is expected to be released in 2026, which could solidify their role in treating chronic diseases [25][26] Pharmaceutical Market Review - The pharmaceutical index increased by 0.14% during the week of February 2-6, outperforming both the ChiNext and CSI 300 indices [32][33] - The total trading volume in the pharmaceutical sector was approximately 475.5 billion yuan, accounting for 3.99% of the total market, which is below the historical average of 7.09% [46] - The report notes that the pharmaceutical sector's performance ranks 14th among all industries for the week, indicating a relatively stable position in the market [35] Investment Opportunities - The report suggests focusing on companies involved in small nucleic acids, particularly those with dual-target strategies and those that have successfully expanded internationally [31] - Key companies to watch include CROs like Tigermed and Baiyue, as well as small nucleic acid firms such as Reebio and Maiwei [4][31] - The report identifies three main investment directions: BD 2.0, small nucleic acids, and supply chain management, emphasizing the potential for high returns in these areas [5]

Core Insights - Oligonucleotide therapies are emerging as a significant breakthrough in the treatment of rare diseases, with over a dozen therapies approved globally and hundreds in clinical research, promising to benefit more patients in the future [1][14][15] Industry Developments - The global landscape has seen more than ten oligonucleotide therapies approved for rare diseases, providing new treatment options for conditions such as Amyotrophic Lateral Sclerosis (ALS), Duchenne Muscular Dystrophy (DMD), and Hemophilia [1][14] - There are currently over a hundred oligonucleotide therapies in clinical development targeting various rare diseases, including siRNA and antisense oligonucleotide (ASO) therapies [2][14] Recent Approvals and Innovations - In August, Ionis Pharmaceuticals received FDA approval for the LICA drug Dawnzera (donidalorsen) for preventing hereditary angioedema (HAE) attacks in patients aged 12 and older, marking it as the first RNA-targeted drug for HAE [4][18] - Ionis Pharmaceuticals and Sobi announced the approval of ASO drug Tryngolza (olezarsen) in the EU for treating genetically confirmed familial chylomicronemia syndrome (FCS) [4][19] - Alnylam Pharmaceuticals' siRNA therapy Amvuttra (vutrisiran) was approved by the FDA in March for treating patients with transthyretin amyloidosis with cardiomyopathy [5][19] Clinical Trial Progress - NS Pharma reported positive results from the long-term extension study of ASO therapy brogidirsen for DMD, showing effective exon 44 skipping and stable maintenance of motor function in patients [7][21] - RIBOMIC's umedaptanib pegol showed promising results in a Phase 2 trial for achondroplasia in children, with many patients experiencing improved height growth rates [7][21] - Ionis Pharmaceuticals' ASO therapy zilganersen demonstrated significant results in stabilizing walking speed in Alexander disease patients, with plans for a new drug application to the FDA in 2026 [8][22] WuXi TIDES Platform - WuXi TIDES has established an integrated solution for oligonucleotide and peptide therapies, covering custom synthesis, conjugation, process development, and CMC, facilitating the transition of innovative projects into clinical stages [1][11][26] - The platform offers comprehensive CRDMO services from drug discovery to commercial production, supporting high-throughput synthesis and custom synthesis for various oligonucleotides [11][26][27] Future Outlook - The company aims to continue leveraging its integrated CRDMO model to empower the development of various new drugs, including oligonucleotide therapies, to bring more effective treatments to patients [12][27]

Core Viewpoint - Alnylam Pharmaceuticals has transformed from a biotech company to a pharmaceutical leader, achieving a market capitalization of approximately $611 billion and aiming for a $100 billion valuation, driven by strong revenue growth and a robust pipeline of RNAi therapies [1][2][21]. Financial Performance - Alnylam's total revenue for the first three quarters of 2025 reached $2.617 billion, with product net revenue of $1.992 billion, marking a 67% year-over-year increase [4]. - The TTR product line saw an 85% revenue growth to $1.628 billion, primarily driven by Amvuttra and Onpattro [4]. - Alnylam's total revenue projections for 2025 have been raised to $2.95-3.05 billion, with TTR product revenue guidance adjusted to $2.475-2.525 billion [4]. Product Pipeline and Collaborations - Alnylam has over 15 projects in its pipeline, focusing on rare diseases, cardiovascular, metabolic, and neurological conditions, with Cemdisiran and Elebsiran in late-stage clinical trials [8][14]. - Strategic collaborations with companies like Novartis and Regeneron have accelerated product development and diversified revenue streams [6][7]. Key Products and Market Potential - Leqvio, a long-acting lipid-lowering drug developed in partnership with Novartis, is expected to exceed $1 billion in sales for the first time in 2025 [16]. - Zilebesiran, a novel hypertension treatment, is anticipated to revolutionize blood pressure management with a convenient dosing schedule [16][21]. Future Outlook - Alnylam's dual revenue model of product sales and licensing agreements supports short-term profitability while its innovative pipeline offers significant long-term growth potential [21]. - The company is well-positioned to achieve its goal of a $100 billion market valuation as it continues to launch impactful therapies [21].